Companies / EPN

EPSILON HEALTHCARE LIMITED

ASX:EPNPharmaceuticals, Biotechnology & Life Sciences
389.1M shares on issueASX (delayed) · as of 28 July 2026$0.023price · delayed$9.3Mmarket cap · indicative
D
Dilution grade

Runway under 2 quarters; options/rights overhang 31% of shares; 31% of shares in the money

Cash runway1.1 quarters of funding
Share-count growth (24m)12.7%
Raise cadence (24m)1 cash raise
Options & rights overhang30.6% of shares
In-the-money supply30.6% of shares
Pending proposed issuesnone

EPSILON HEALTHCARE LIMITED's ordinary share count rose 12.7% between December 2024 and February 2026, to 389M shares. The company completed one capital raise in the 24‑month window, raising A$555K in May 2025, for total disclosed proceeds of A$555K. Options and rights on issue could convert into 119M new shares, equal to 30.6% of the current share count, with 31% of current shares represented by in‑the‑money securities; the nearest expiry is June 2028. At the March 2026 quarter the company reported A$232K in available cash, about 1.1 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
30.6%
Max option dilution
30.6%
ITM option dilution
0
Raises · last 12 months
1.1 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 389.1M per ASX (delayed) (28 July 2026).
319.0M344.7M370.5MDec 24Sept 25July 26Cash raise · 14 May 2025

Cash runway

1.1 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$232k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
8 June 20263G · unquotedEPN : ORDINARY FULLY PAID389.1MAppendix 3G
11 Feb 20262A · quoted issueEPN : ORDINARY FULLY PAID389.1MAppendix 2A
5 Feb 20262A · quoted issueEPN : ORDINARY FULLY PAID384.1MAppendix 2A
14 Sept 20252A · quoted issueEPN : ORDINARY FULLY PAID379.1MAppendix 2A
10 Sept 20253H · cancellationEPN : ORDINARY FULLY PAID373.1MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 0 in the last 12 months

$555k
Capital raise
14 May 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

30.6%
Total overhang · of current shares
30.6%
In the money · at current price
119.0M
Potential new shares
June 2028
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
3 July 2026Zoe HutchingsBuy1.5M—$30k3Y notice
5 June 2026Peter GiannopoulosOther—22.0M—3Y notice
5 June 2026Alan Preston BeasleyBuy11.1M20.0M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

8 July 2026Change in substantial holding
8 July 2026Becoming a substantial holder
6 July 2026Change of Director's Interest Notice - Zoe Hutchings
30 June 2026Company Debt Arrangements - update
26 June 2026Closure of small holding share sale facility
8 June 2026Notification regarding unquoted securities - EPN
8 June 2026Change of Director's Interest Notice - Peter Giannopoulos
8 June 2026Change of Director's Interest Notice - Alan Beasley
29 May 2026Results of Meeting
11 May 2026Change of Director's Interest Notice - Alan Beasley
8 May 2026Small holding share sale facility
29 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
29 Apr 2026Notice of Annual General Meeting/Proxy Form
14 Apr 2026Update on proceedings against former director
31 Mar 2026Annual Report to shareholders
31 Mar 2026Appendix 4G & Corporate Governance Statement
27 Feb 2026$PPreliminary Final Report
17 Feb 2026Establishment of New Epsilon Biotech Subsidiary
11 Feb 2026Application for quotation of securities - EPN
6 Feb 2026Becoming a substantial holder

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.